

October 22, 2013 WILMINGTON, Del. Media Contact:

Patty Seif 302-774-4482 patricia.r.seif@dupont.com 302-774-4994

Investor Contact:

# DuPont Delivers 3Q 2013 Operating Earnings of \$.45 per Share Sales Increase on Higher Volume

WILMINGTON, Del., Oct. 22, 2013 – DuPont today announced third quarter 2013 operating earnings of \$.45 per share compared to \$.43 per share in the prior year. GAAP<sup>1</sup> earnings from continuing operations were \$.28 per share versus a loss of \$.05 per share for the third quarter 2012. Third quarter results principally reflect overall top-line growth and earnings improvements for Performance Materials, Electronics & Communications and Safety & Protection, and a lower effective tax rate. This was offset by expected lower earnings for Performance Chemicals.

# Highlights

- Third quarter net sales of \$7.7 billion increased 5 percent, with volume up 9 percent versus a weak prior year. Sales also reflect 3 percent lower local prices and a 1 percent negative currency impact.
- Excluding Performance Chemicals, all operating segments posted increased operating earnings versus last year. Performance Materials, Electronics & Communications, Safety & Protection and Industrial Biosciences had double-digit earnings growth reflecting higher volumes and improved margins.
- Agriculture sales grew 15 percent driven by increased insecticide volumes and higher seed prices in Latin America. The sales growth and the benefit of increased ownership in Pannar Seed (Pty) Ltd. reduced the segment's third quarter seasonal loss to \$62 million.
- Cost productivity gains and restructuring savings are on track to meet or exceed full-year targets.
- The company continues to expect full-year operating earnings of about \$3.85 per share.

"We executed well against our plans. Third quarter sales volumes and operating earnings were stronger across most businesses compared to a soft quarter last year," said DuPont Chair and CEO Ellen Kullman. "While we expect overall sequential growth in industrial market demand will remain subdued, fourth quarter operating earnings will be up substantially from last year. For the full year we are on track to deliver modest earnings growth, despite the significant decline in Performance Chemicals' results."

<sup>1</sup>Generally Accepted Accounting Principles (GAAP)

# **Global Consolidated Net Sales – 3rd Quarter**

Third quarter 2013 net sales were \$7.7 billion, up 5 percent versus last year, reflecting 9 percent higher volume, partly offset by 3 percent lower local selling prices and 1 percent negative currency impact. The table below shows third quarter regional sales and variances versus third quarter 2012.

		nths Ended er 30, 2013	Perce	-		
(Dollars in millions)	\$	% Change	Local Price	Currency Effect	Volume	Portfolio/ Other
U.S. & Canada	\$ 2,548	3	(1)	-	5	(1)
EMEA*	1,814	10	(5)	2	10	3
Asia Pacific	1,944	3	(6)	(3)	12	-
Latin America	 1,429	4	-	(4)	8	-
Total Consolidated Sales	\$ 7,735	5	(3)	(1)	9	-

# \* Europe, Middle East & Africa

# <u>Segment Sales – 3rd Quarter</u>

The table below shows third quarter 2013 segment sales with related variances versus the prior year.

SEGMENT SALES	T	hree Mon	ths Ended	Percentage Change			
(Dollars in millions)	S	eptember	30, 2013				
				USD		Portfolio/	
		\$	% Change	Price	Volume	Other	
Agriculture	\$	1,633	15	1	10	4	
Electronics & Communications		638	5	(9)	14	-	
Industrial Biosciences		305	4	-	4	-	
Nutrition & Health		868	(1)	1	(1)	(1)	
Performance Chemicals		1,720	(1)	(13)	12	-	
Performance Materials		1,663	3	(2)	6	(1)	
Safety & Protection		985	5	-	5	-	
Other		1	nm				
Total segment sales		7,813					
Elimination of transfers		(78)					
Consolidated net sales	\$	7,735					

# **Operating Earnings – 3rd Quarter**

					 Change v	rs. 2012
(Dollars in millions)	3Q	013	30	Q12	\$	%
Agriculture	\$	(62)	\$	(70)	\$ 8	11%
Electronics & Communications		97		58	39	67%
Industrial Biosciences		45		40	5	13%
Nutrition & Health		81		77	4	5%
Performance Chemicals		254		413	(159)	-38%
Performance Materials		374		331	43	13%
Safety & Protection		171		147	24	16%
Other		(112)		(85)	 (27)	nm
		848		911	 (63)	-7%
Pharmaceuticals		5		10	 (5)	-50%
Total segment operating earnings <sup>(1)</sup>		853		921	(68)	-7%
Corporate expenses		(162)		(174)	12	nm
Interest expense		(108)		(116)	 8	nm
Operating earnings before income taxes and exchange gains/losses		583		631	(48)	-8%
Provision for income taxes on operating earnings, excluding taxes						
on exchange gains/losses	(	(111)		(164)	53	nm
Net after-tax exchange gains (losses) <sup>(2)</sup>		(43)		(59)	16	nm
Net income attributable to noncontrolling interests		(3)		(3)	 -	nm
Operating earnings	\$	426	\$	405	\$ 21	5%
Operating earnings per share	\$	0.45	\$	0.43	\$ 0.02	5%

(1) See Schedules B and C for listing of significant items and their impact by segment.

(2) See Schedule D for additional information on exchange gains and losses.

The following is a summary of business results for each of the company's reportable segments in the third quarter comparing the current quarter with the prior year. References to selling price are on a U.S. dollar basis, including the impact of currency.

**Agriculture** – A seasonal operating loss of \$62 million improved \$8 million. The improvement was driven by strong insecticide demand as growers anticipate heavy insect pressure in Latin America, price improvement in seeds, and a \$26 million gain resulting from the acquisition of a controlling interest in Pannar. These increases were offset by higher seed costs reflecting finalization of the northern hemisphere season, continued investment to drive future growth and a negative currency impact.

**Electronics & Communications** – Operating earnings of \$97 million increased \$39 million driven by higher sales volume, mainly in photovoltaic markets reflecting demand improvement and share gains. Higher volume was offset in part by reduced selling prices, mainly from pass-through of lower metals prices.

**Industrial Biosciences** – Operating earnings of \$45 million were up 13 percent on higher sales of Sorona<sup>®</sup> polymer for carpeting and apparel and lower costs, partially offset by higher raw material costs.

**Nutrition & Health** – Operating earnings of \$81 million increased 5 percent reflecting productivity improvements, partially offset by higher cost guar inventory and negative currency.

**Performance Chemicals** – Operating earnings of \$254 million were \$159 million lower as price declines for titanium dioxide, refrigerants and fluoropolymers, along with higher raw material inventory costs, principally ore costs, more than offset volume increases. Titanium dioxide volume was up 25 percent from third quarter 2012 and essentially flat on a sequential basis.

**Performance Materials** – Operating earnings of \$374 million increased \$43 million including a \$30 million benefit from a joint venture. Earnings improvement from higher volume reflecting increased demand in packaging, automotive, and electronics markets was partially offset by lower selling prices.

**Safety & Protection** – Operating earnings of \$171 million increased \$24 million due primarily to higher volume and productivity improvements, partially offset by weaker sales mix. Higher volume reflects increased demand for U.S. ballistics military protection, protective garments, and construction products that offset softness in global public sector spending.

Additional information is available on the DuPont Investor Center website at http://www.investors.dupont.com.

## **Outlook**

The company continues to expect full-year operating earnings of about \$3.85 per share, with some changes in underlying assumptions. The company now anticipates slightly lower full-year growth rates for global GDP and industrial production, a larger negative currency impact and a lower base tax rate of about 22 percent.

## **Use of Non-GAAP Measures**

Management believes that certain non-GAAP measurements are meaningful to investors because they provide insight with respect to ongoing operating results of the company. Such measurements are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance. Reconciliations of non-GAAP measures to GAAP are provided in schedules A, C and D.

DuPont (NYSE: DD) has been bringing world-class science and engineering to the global marketplace in the form of innovative products, materials, and services since 1802. The company believes that by collaborating with customers, governments, NGOs, and thought leaders we can help find solutions to such global challenges as providing enough healthy food for people everywhere, decreasing dependence on fossil fuels, and protecting life and the environment. For additional information about DuPont and its commitment to inclusive innovation, please visit http://www.dupont.com.

Forward-Looking Statements: This news release contains forward-looking statements which may be identified by their use of words like "plans," "expects," "will," "believes," "intends," "estimates," "anticipates" or other words of similar meaning. All statements that address expectations or projections about the future, including statements about the company's growth strategy, product development, regulatory approval, market position, anticipated benefits of acquisitions, outcome of contingencies, such as litigation and environmental matters, expenditures and financial results, are forward-looking statements. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond the company's control. Some of the important factors that could cause the company's actual results to differ materially from those projected in any such forward-looking statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; significant litigation and environmental matters; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, weather events and natural disasters; ability to protect and enforce the company's intellectual property rights; and successful integration of acquired businesses and separation of underperforming or non-strategic assets or businesses. The company undertakes no duty to update any forward-looking statements as a result of future developments or new information.

# # #

10/22/13

#### E. I. du Pont de Nemours and Company Consolidated Income Statements (Dollars in millions, except per share amounts )

#### SCHEDULE A

SCHEDULE A		onths Ended ember 30,		nths Ended nber 30,		
	2013	2012	2013	2012		
Net sales	\$ 7,735	\$ 7,390	\$ 27,987	\$ 27,487		
Other income (loss), net <sup>(a)</sup>	70	(54)	321	251		
Total	7,805	7,336	28,308	27,738		
Cost of goods sold	5,165	4,779	17,415	16,558		
Other operating charges <sup>(a)</sup>	990	937	2,843	3,064		
Selling, general and administrative expenses	774	764	2,740	2,691		
Research and development expense	540	521	1,603	1,562		
Interest expense	108	116	340	347		
Employee separation / asset related charges, net (a)		394		394		
Total	7,577	7,511	24,941	24,616		
Income (loss) from continuing operations before income taxes	228	(175)	3,367	3,122		
(Benefit from) provision for income taxes on continuing operations (a)	(35)		687	654		
Income from continuing operations after income taxes	263	(40)		2,468		
Income from discontinued operations after taxes	25	48	1,997	219		
Net income	288	8	4,677	2,687		
Less: Net income attributable to noncontrolling interests	3	3	14	24		
Net income attributable to DuPont	\$ 285	\$ 5	\$ 4,663	\$ 2,663		
Basic earnings per share of common stock <sup>(b)</sup> :						
Basic earnings (loss) per share of common stock from continuing operations	\$ 0.28	\$ (0.05)	\$ 2.87	\$ 2.61		
Basic earnings per share of common stock from discontinued operations	0.03	0.05	2.16	0.24		
Basic earnings per share of common stock	\$ 0.30	\$ -	\$ 5.03	\$ 2.85		
Diluted earnings per share of common stock <sup>(b)</sup> :						
Diluted earnings (loss) per share of common stock from continuing operations	\$ 0.28	\$ (0.05)	\$ 2.85	\$ 2.58		
Diluted earnings per share of common stock from discontinued operations Diluted earnings per share of common stock	<u>0.03</u> \$ 0.30	<u> </u>	\$ 4.99	<u>0.23</u> \$ 2.82		
Diruce carnings per snare of common stock	\$ 0.50	<del>م</del> -	\$ 4.77	\$ 2.82		
Dividends per share of common stock	\$ 0.45	\$ 0.43	\$ 1.33	\$ 1.27		
Average number of shares outstanding used in earnings per share (EPS) calculation: Basic Diluted	925,645,000 933,005,000	931,737,000 940,526,000	925,548,000 932,542,000	933,227,000 942,524,000		

(a) See Schedule B for detail of significant items.(b) The sum of the individual earnings per share amounts may not equal the total due to rounding.

#### Reconciliation of Non-GAAP Measures

#### Summary of Earnings Comparison Three Months Ended Nine Months Ended September 30, September 30, % % Change 2012 2013 2012 2013 Change 1ge 758% \$ Income from continuing operations after income taxes (GAAP) 263 \$ (40) 2,680 \$ 2,468 \$ Less: Significant items benefit (charge) included in income from Significant terms benefit (charge) included in income for a continuing operations after income taxes (per Schedule B) Non-operating pension/OPEB costs included in income from continuing operations after income taxes Net income attributable to noncontrolling interest exists expressed. (71) (342) (129) (589) (340) (95) (106) (279) 24 3,373 14 3 3 405 426 3,074 Operating earnings \$ \$ 5% \$ \$ -9% EPS from continuing operations (GAAP) \$ 0.28 \$ (0.05) 660% \$ 2.85 \$ 2.58 10% Significant items benefit (charge) included in EPS (per Schedule B) Non-operating pension/OPEB costs included in EPS Operating EPS (0.08)(0.37) (0.14) (0.63)(<u>0.09)</u> (0.11)(0.30) (0.36) -8% 0.45 \$ 0.43 5% \$ 3.29 3.57 \$

# E. I. du Pont de Nemours and Company Condensed Consolidated Balance Sheets

(Dollars in millions, except per share amounts )

# **SCHEDULE A (continued)**

	Sept	tember 30, 2013	December 31, 2012	
Assets				
Current assets				
Cash and cash equivalents	\$	7,005	\$	4,284
Marketable securities		184		123
Accounts and notes receivable, net		8,298		5,452
Inventories		7,031		7,565
Prepaid expenses		185		204
Deferred income taxes		840		613
Assets held for sale		-		3,076
Total current assets		23,543		21,317
Property, plant and equipment, net of accumulated depreciation		1.0.000		
(September 30, 2013 - \$19,779; December 31, 2012 - \$19,085)		12,908		12,741
Goodwill		4,718		4,616
Other intangible assets		5,135		5,126
Investment in affiliates		1,054		1,163
Deferred income taxes		3,739		3,936
Other assets		893		960
Total	\$	51,990	\$	49,859
Liabilities and Equity				
Current liabilities				
Accounts payable	\$	3,876	\$	4,853
Short-term borrowings and capital lease obligations		4,204		1,275
Income taxes		442		343
Other accrued liabilities		3,874		5,997
Liabilities related to assets held for sale		-		1,084
Total current liabilities		12,396		13,552
Long-term borrowings and capital lease obligations		10,755		10,465
Other liabilities		13,901		14,687
Deferred income taxes		973		856
Total liabilities		38,025		39,560
Commitments and contingent liabilities				
Redeemable noncontrolling interest		65		-
Stockholders' equity		227		027
Preferred stock		237		237
Common stock, \$0.30 par value; 1,800,000,000 shares authorized; Issued at September 30, 2013 - 1,013,111,000 ; December 31, 2012 - 1,020,057,000		304		306
Additional paid-in capital		11,007		10,655
Reinvested earnings		17,020		14,383
Accumulated other comprehensive loss		(8,000)		(8,646)
Common stock held in treasury, at cost (87,041,000 shares				
at September 30, 2013 and December 31, 2012)		(6,727)		(6,727)
Total DuPont stockholders' equity		13,841		10,208
Noncontrolling interests		59		91
Total equity		13,900		10,299
Total	\$	51,990	\$	49,859

## E. I. du Pont de Nemours and Company Condensed Consolidated Statement of Cash Flows (Dollars in millions)

## SCHEDULE A (continued)

SCHEDULE A (continueu)		hs Ended per 30,		
Total Company		2013	 2012	
Net income	\$	4,677	\$ 2,687	
Adjustments to reconcile net income to cash used for operating activities:		0.44		
Depreciation		961	1,047	
Amortization		255	266	
Other operating charges and credits - net		447	907	
Gain on sale of business		(2,689)	-	
Contributions to pension plans		(246)	(762)	
Change in operating assets and liabilities - net		(5,738)	 (4,571)	
Cash used for operating activities		(2,333)	(426)	
Investing activities				
Purchases of property, plant and equipment		(1,223)	(1,139)	
Investments in affiliates		(43)	(31)	
Payments for businesses - net of cash acquired		(133)	(18)	
Proceeds from sale of business - net		4,816	-	
Proceeds from sales of assets - net		126	175	
Net (increase) decrease in short-term financial instruments		(78)	336	
Forward exchange contract settlements		82	23	
Other investing activities - net		31	 (13)	
Cash provided by (used for) investing activities		3,578	(667)	
Financing activities				
Dividends paid to stockholders		(1,242)	(1,191)	
Net increase in borrowings		3,204	2,524	
Repurchase of common stock		(1,000)	(400)	
Proceeds from exercise of stock options		497	520	
Payments for noncontrolling interest		-	(447)	
Other financing activities - net		3	 38	
Cash provided by financing activities		1,462	1,044	
Effect of exchange rate changes on cash		(81)	(23)	
Cash classified as held for sale			 (96)	
Increase (decrease) in cash and cash equivalents		2,626	(168)	
Cash and cash equivalents at beginning of period		4,379	 3,586	
Cash and cash equivalents at end of period	\$	7,005	\$ 3,418	

## Reconciliation of Non-GAAP Measure

## **Calculation of Free Cash Flow - Total Company**

	 September 30,			
	 2013 2012			
Cash used for operating activities	\$ (2,333)	\$	(426)	
Purchases of property, plant and equipment	 (1,223)		(1,139)	
Free cash flow	\$ (3,556) \$ (1,565		(1,565)	

Nine Months Ended

### SCHEDULE B

#### SIGNIFICANT ITEMS FROM CONTINUING OPERATIONS

		Pre	-tax			Afte	r-tax		(\$ Per	Share	)
	2	013	2	2012	2	013	2	2012	2013	2	2012
1st Quarter											
Customer claims charge <sup>(a)</sup>	\$	(35)	\$	(50)	\$	(22)	\$	(32)	\$ (0.02)	\$	(0.04)
Income tax items <sup>(b)</sup>		-		-		42		-	 0.04		-
1st Quarter - Total	\$	(35)	\$	(50)	\$	20	\$	(32)	\$ 0.02	\$	(0.04)
2nd Quarter											
Customer claims charge <sup>(a)</sup>	\$	(80)	\$	(265)	\$	(51)	\$	(169)	\$ (0.05)	\$	(0.18)
Income tax items <sup>(c)</sup>		(11)		-		(27)		-	(0.03)		-
Litigation settlement <sup>(d)</sup>		-		(137)		-		(123)	-		(0.13)
Gain on sale of equity method investment(e)		-		122		-		77	 -		0.08
2nd Quarter - Total	\$	(91)	\$	(280)	\$	(78)	\$	(215)	\$ (0.08)	\$	(0.23)
3rd Quarter											
Customer claims charge <sup>(a)</sup>	\$	(40)	\$	(125)	\$	(24)	\$	(80)	\$ (0.03)	\$	(0.09)
Litigation settlement <sup>(f)</sup>		(72)		-		(47)		-	(0.05)		-
Restructuring charge <sup>(g)</sup>		-		(152)		-		(105)	-		(0.11)
Asset impairment charge <sup>(h)</sup>		-		(242)		-		(157)	-		(0.17)
3rd Quarter - Total	\$	(112)	\$	(519)	\$	(71)	\$	(342)	\$ (0.08)	\$	(0.37)
Year-to-date - Total <sup>(i)</sup>	\$	(238)	\$	(849)	\$	(129)	\$	(589)	\$ (0.14)	\$	(0.63)

(a) Third quarter 2013 includes a net charge of \$(40) consisting of a \$(65) charge associated with the company's process to fairly resolve claims related to the use of Imprelis® herbicide offset by \$25 of insurance recoveries. At September 30, 2013, the company has recorded charges of \$(930) to resolve these claims. The company will continue to evaluate reported claim damage as additional information becomes available. It is reasonably possible that additional charges could result related to this matter and the company currently estimates that total charges could be about \$1,200. The company has an applicable insurance program with a deductible equal to the first \$100 of costs and expenses. The insurance program limits are \$725 for costs and expenses of the \$100. The company has submitted and will continue to submit requests for payment to its insurance carriers for costs associated with this matter. The company has begun to receive payment from its insurance carriers and continues to seek recovery although the timing and outcome remain uncertain. These charges are recorded in Other operating charges and relate to the Agriculture segment.

- (b) First quarter 2013 included a net tax benefit of \$42 consisting of a \$68 benefit for the 2013 extension of certain U.S business tax provisions offset by a (\$26) charge related to the global distribution of Performance Coatings cash proceeds.
- (c) Second quarter 2013 included a charge of (\$11) in Other income, net related to interest on a prior year tax position. Second quarter 2013 also included a charge of (\$49) associated with a change in accrual for a prior year tax position (inclusive of a benefit associated with interest on a prior year tax position) offset by a \$33 benefit for an enacted tax law change.
- (d) Second quarter 2012 included a charge of (\$137) recorded in Other operating charges primarily related to the company's settlement of litigation with Invista. This matter relates to Other.
- (e) Second quarter 2012 included a pre-tax gain of \$122 recorded in Other income, net associated with the sale of an equity method investment in the Electronics & Communications segment.
- (f) Third quarter 2013 includes a charge of \$(72) recorded in Other operating charges related to the company's settlement of titanium dioxide antitrust litigation. This matter relates to the Performance Chemicals segment.
- (g) Third quarter 2012 included a \$152 restructuring charge recorded in Employee separation/asset related charges, net consisting of \$133 of severance and related benefit costs and \$19 of asset related charges as a result of the company's plan to eliminate corporate costs previously allocated to Performance Coatings and cost-cutting actions to improve competitiveness. Pre-tax charges by segmer were: Agriculture - \$(3), Nutrition & Health - \$(13), Electronics & Communications - \$(7), Performance Chemicals - \$(3), Performance Materials - \$(9), Safety & Protection - \$(55), Industrial Biosciences - \$(3), and Corporate expenses - \$(59).
- (h) Third quarter 2012 included a \$242 impairment charge recorded in Employee separation/asset related charges, net related to asset groupings within the Electronics & Communications and Performance Materials segments. The charge of \$150 within Electronics & Communications was a result of conditions within the thin film photovoltaic market. The charge of \$92 within Performance Materials was the result of deteriorating conditions in an industrial polymer market.

(i)

Earnings per share for the year may not equal the sum of quarterly earnings per share due to changes in average share calculations.

# E. I. du Pont de Nemours and Company Consolidated Segment Information (Dollars in millions)

# SCHEDULE C

		Three Months Ended September 30,				
SEGMENT SALES (1)	2013	2012	2013	2012		
Agriculture	\$ 1,633	\$ 1,423	\$ 9,933	\$ 8,891		
Electronics & Communications	638	607	1,907	2,079		
Industrial Biosciences	305	292	898	880		
Nutrition & Health	868	876	2,601	2,569		
Performance Chemicals	1,720	1,732	5,087	5,600		
Performance Materials	1,663	1,614	4,892	4,913		
Safety & Protection	985	934	2,909	2,861		
Other	1	2	5	4		
Total Segment sales	7,813	7,480	28,232	27,797		
Elimination of transfers	(78)	(90)	(245)	(310)		
Consolidated net sales	\$ 7,735	\$ 7,390	\$ 27,987	\$ 27,487		

(1) Sales for the reporting segments include transfers.

#### E. I. du Pont de Nemours and Company Consolidated Segment Information (Dollars in millions)

## SCHEDULE C (continued)

				onths Ended mber 30,	
INCOME/(LOSS) FROM CONTINUING OPERATIONS (GAAP)	2013	2012	2013	2012	
Agriculture	\$ (102)	\$ (198)	\$ 2,240	\$ 1,772	
Electronics & Communications	97	(99)	241	181	
Industrial Biosciences	45	37	129	118	
Nutrition & Health	81	64	218	248	
Performance Chemicals	182	410	697	1,575	
Performance Materials	374	230	1,002	851	
Safety & Protection	171	92	481	432	
Pharmaceuticals	5	10	27	53	
Other	(112)	(85)	(276)	(385)	
Total Segment PTOI	741	461	4,759	4,845	
Corporate expenses	(162)	(233)	(582)	(708)	
Interest expense	(108)	(116)	(340)	(347)	
Non-operating pension/OPEB costs	(142)	(157)	(415)	(507)	
Net exchange gains (losses) <sup>(1)</sup>	(101)	(130)	(55)	(161)	
Income before income taxes from continuing operations	\$ 228	\$ (175)	\$ 3,367	\$ 3,122	

	Three Mon Septem		Nine Mon Septem	
SIGNIFICANT ITEMS BY SEGMENT (PRE-TAX) <sup>(2)</sup>	2013	2012	2013	2012
Agriculture	\$ (40)	\$ (128)	\$ (155)	\$ (443)
Electronics & Communications	-	(157)	-	(35)
Industrial Biosciences	-	(3)	-	(3)
Nutrition & Health	-	(13)	-	(13)
Performance Chemicals	(72)	(3)	(72)	(3)
Performance Materials	-	(101)	-	(101)
Safety & Protection	-	(55)	-	(55)
Pharmaceuticals	-	-	-	-
Other	-	-		(137)
Total significant items by segment	(112)	(460)	(227)	(790)
Corporate expenses	-	(59)	(11)	(59)
Total significant items before income taxes	\$ (112)	\$ (519)	\$ (238)	\$ (849)

		onths Ended nber 30,			
OPERATING EARNINGS	2013	2012	2013	2012	
Agriculture	\$ (62)	\$ (70)	\$ 2,395	\$ 2,215	
Electronics & Communications	97	58	241	216	
Industrial Biosciences	45	40	129	121	
Nutrition & Health	81	77	218	261	
Performance Chemicals	254	413	769	1,578	
Performance Materials	374	331	1,002	952	
Safety & Protection	171	147	481	487	
Pharmaceuticals	5	10	27	53	
Other	(112)	(85)	(276)	(248)	
Total segment operating earnings	853	921	4,986	5,635	
Corporate expenses	(162)	(174)	(571)	(649)	
Interest expense	(108)	(116)	(340)	(347)	
Operating earnings before income taxes and exchange gains (losses)	583	631	4,075	4,639	
Net exchange gains (losses) <sup>(1)</sup>	(101)	(130)	(55)	(161)	
Operating earnings before income taxes	\$ 482	\$ 501	\$ 4,020	\$ 4,478	

(1) See Schedule D for additional information on exchange gains and losses.

(2) See Schedule B for detail of significant items.

# E. I. du Pont de Nemours and Company Reconciliation of Non-GAAP Measures (Dollars in millions, except per share amounts)

## **SCHEDULE D**

## Reconciliations of Adjusted EBIT / EBITDA to Consolidated Income

	Three Months Ended September 30,				Nine Months Ended September 30,				
	2	2013	2012			2013		2012	
Income from continuing operations before income taxes	\$	228	\$	(175)	\$	3,367	\$	3,122	
Add: Significant items before income taxes		112		519		238		849	
Add: Non-operating pension/OPEB costs		142		157		415		507	
Operating earnings before income taxes	\$	482	\$	501	\$	4,020	\$	4,478	
Less: Net income attributable to noncontrolling		3		3		14		24	
Add: Interest expense		108		116		340		347	
Adjusted EBIT from operating earnings		587		614		4,346		4,801	
Add: Depreciation and amortization		379		393		1,216		1,237	
Adjusted EBITDA from operating earnings	\$	966	\$	1,007	\$	5,562	\$	6,038	

## **Reconciliation of Operating Earnings Per Share (EPS) Outlook**

The reconciliation below represents the company's outlook on an operating earnings basis, defined as earnings from continuing operations excluding significant items and non-operating pension/OPEB costs.

	Year Ended December 31,						
	2013	Outlook	2012 Actual				
Operating EPS	\$	3.85	\$	3.77			
Significant items							
Tax items		0.02		-			
Sale of an equity method investment		-		0.08			
Customer claims charges		(0.11)		(0.39)			
Restructuring charge/adjustments		-		(0.17)			
Litigation settlement		(0.05)		(0.13)			
Asset impairment charge		-		(0.19)			
Sale of business		-		0.08			
Non-operating pension/OPEB costs - estimate		(0.40)		(0.46)			
Impact of LIFO accounting change		-		0.02			
EPS from continuing operations (GAAP)	\$	3.31	\$	2.61			

#### E. I. du Pont de Nemours and Company Reconciliation of Non-GAAP Measures (Dollars in millions)

#### SCHEDULE D (continued)

#### **Exchange Gains/Losses on Operating Earnings**

The company routinely uses forward exchange contracts to offset its net exposures, by currency, related to the foreign currency denominated monetary assets and liabilities of its operations. The objective of this program is to maintain an approximately balanced position in foreign currencies in order to minimize, on an aftertax basis, the effects of exchange rate changes. The net pre-tax exchange gains and losses are recorded in Other income, net and the related tax impact is recorded in Provision for (benefit from) income taxes on the Consolidated Income Statements.

	Three Months Ended				Nine Months Ended September 30,			
	September 30,							
	2013		2012		2013		2012	
Subsidiary/Affiliate Monetary Position Gain (Loss)								
Pre-tax exchange gains (losses) (includes equity affiliates)	\$	29	\$	91	\$	(121)	\$	(50)
Local tax benefits (expenses)		13		(6)		32		10
Net after-tax impact from subsidiary exchange gains (losses)	\$	42	\$	85	\$	(89)	\$	(40)
Hedging Program Gain (Loss)								
Pre-tax exchange gains (losses)	\$	(130)	\$	(221)	\$	66	\$	(111)
Tax benefits (expenses)		45		77		(24)		38
Net after-tax impact from hedging program exchange gains (losses)	\$	(85)	\$	(144)	\$	42	\$	(73)
Total Exchange Gain (Loss)								
Pre-tax exchange gains (losses)	\$	(101)	\$	(130)	\$	(55)	\$	(161)
Tax benefits (expenses)		58		71		8		48
Net after-tax exchange gains (losses) <sup>(1)</sup>	\$	(43)	\$	(59)	\$	(47)	\$	(113)

As shown above, the "Total Exchange Gain (Loss)" is the sum of the "Subsidiary/Affiliate Monetary Position Gain (Loss)" and the "Hedging Program Gain (Loss)."

(1) The above Net after-tax exchange gains (losses) excludes gains (losses) attributable to discontinued operations of \$0 and \$9 for the three months ended September 30, 2013 and 2012, respectively, and \$(5) and \$(11) for the nine months ended September 30, 2013 and 2012, respectively.

#### Reconciliation of Base Income Tax Rate to Effective Income Tax Rate

Base income tax rate is defined as the effective income tax rate less the effect of exchange gains (losses), as defined above, significant items and non-operating pension/OPEB costs.

		onths Ended mber 30,	Nine Months Ended September 30,			
	2013	2012	2013	2012		
Income from continuing operations before income taxes	\$ 228	\$ (175)	\$ 3,367	\$ 3,122		
Add: Significant items - (benefit) charge <sup>(2)</sup>	112	519	238	849		
Non-operating pension/OPEB costs	142	157	415	507		
Less: Net exchange (losses) gains	(101)	(130)	(55)	(161)		
Income from continuing operations before income taxes, significant items, exchange gains (losses), and non-operating pension/OPEB costs	\$ 583	\$ 631	\$ 4,075	\$ 4,639		
8. (	<i>\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ </i>	<u> </u>	\$ 1,070	\$ 1,000		
Provision for income taxes on continuing operations	\$ (35)	\$ (135)	\$ 687	\$ 654		
Add: Tax benefits (expenses) on significant items	41	177	109	260		
Tax benefits (expenses) on non-operating pension/OPEB costs	47	51	136	167		
Tax benefits (expenses) on exchange gains/losses	58	71	8	48		
Provision for income taxes on operating earnings, excluding exchange gains (losses)	\$ 111	\$ 164	\$ 940	\$ 1,129		
Effective income tax rate	(15.4%)	77.1%	20.4%	20.9%		
Significant items effect and non-operating pension/OPEB costs effect	26.4%	(58.5%)	2.8%	3.2%		
Tax rate, from continuing operations, before significant items and non-operating pension/OPEB costs	11.0%	18.6%	23.2%	24.1%		
Exchange gains (losses) effect	8.0%	7.4%	(0.1%)	0.2%		
Base income tax rate from continuing operations	19.0%	26.0%	23.1%	24.3%		

(2) See Schedule B for detail of significant items.